Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Post by Brinkleyon Feb 27, 2014 10:22am

188 Views

Post# 22258298

Top line results

Measured Values

	STS Arm (Sodium Thiosulfate Treatment)	Observation Arm (No Sodium Thiosulfate Treatment)
Number of Participants Analyzed [units: participants]	49	56
Incidence of Hearing Loss [units: participants]
With hearing loss	14	31
Without hearing loss	35	25

Looks like we have roughly 50% improvement over no treatment at all.

I am assuming that of the children with hearing loss it is less severe in the ones that took STS

I think this would be very well recieved by parents and the FDA.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity